Abbott Laboratories (ABT) Stake Maintained by Shelter Mutual Insurance Co

Shelter Mutual Insurance Co held its position in shares of Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 102,100 shares of the healthcare product maker’s stock at the end of the 2nd quarter. Shelter Mutual Insurance Co’s holdings in Abbott Laboratories were worth $4,963,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in ABT. State Street Corp raised its holdings in shares of Abbott Laboratories by 18.9% in the 1st quarter. State Street Corp now owns 80,499,469 shares of the healthcare product maker’s stock valued at $3,574,987,000 after acquiring an additional 12,806,535 shares in the last quarter. Boston Partners raised its holdings in shares of Abbott Laboratories by 5,663.7% in the 1st quarter. Boston Partners now owns 8,212,035 shares of the healthcare product maker’s stock valued at $364,696,000 after acquiring an additional 8,069,557 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Abbott Laboratories by 11.0% in the 1st quarter. Bank of New York Mellon Corp now owns 33,796,869 shares of the healthcare product maker’s stock valued at $1,500,920,000 after acquiring an additional 3,344,508 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in shares of Abbott Laboratories by 33.8% in the 1st quarter. Ameriprise Financial Inc. now owns 8,823,399 shares of the healthcare product maker’s stock valued at $391,841,000 after acquiring an additional 2,231,316 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Abbott Laboratories by 45.3% in the 1st quarter. Swiss National Bank now owns 6,528,788 shares of the healthcare product maker’s stock valued at $289,943,000 after acquiring an additional 2,035,170 shares in the last quarter. 70.64% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://sportsperspectives.com/2017/11/17/abbott-laboratories-abt-stake-maintained-by-shelter-mutual-insurance-co.html.

A number of brokerages recently weighed in on ABT. Cowen and Company reissued a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Thursday, August 17th. Stifel Nicolaus reissued a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a report on Friday, July 21st. BidaskClub cut Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. BMO Capital Markets reissued a “market perform” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $58.00 price objective on shares of Abbott Laboratories in a report on Thursday, August 3rd. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $56.81.

Abbott Laboratories (NYSE:ABT) opened at $55.54 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.26 and a debt-to-equity ratio of 0.72. Abbott Laboratories has a 1 year low of $37.38 and a 1 year high of $56.69. The stock has a market capitalization of $95,437.16, a P/E ratio of 22.75, a P/E/G ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion for the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. During the same period last year, the company earned $0.59 EPS. analysts predict that Abbott Laboratories will post 2.5 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th were given a $0.265 dividend. The ex-dividend date was Thursday, October 12th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.91%. Abbott Laboratories’s dividend payout ratio is currently 83.47%.

In other news, insider Jaime Contreras sold 52,700 shares of Abbott Laboratories stock in a transaction that occurred on Friday, September 22nd. The stock was sold at an average price of $51.97, for a total value of $2,738,819.00. Following the sale, the insider now directly owns 58,739 shares in the company, valued at approximately $3,052,665.83. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of Abbott Laboratories stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $56.21, for a total value of $5,430,054.63. Following the completion of the sale, the executive vice president now owns 142,082 shares in the company, valued at $7,986,429.22. The disclosure for this sale can be found here. Over the last quarter, insiders sold 282,920 shares of company stock worth $15,389,766. Corporate insiders own 0.76% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply